MinervaX ApS

MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS), which is responsible for 50% of life-threatening infections in new-born.

Contact name:

Per Fischer


Ole Maaløes Vej 3, 2200 Copenhagen, Denmark

Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2013 DANISH BIO – DANSK BIOTEK. All rights reserved.